---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205129"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:23:14.868949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances

## Summary
- Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.
- GAAP net loss $125.4M ($2.86/share) vs $3.8M ($0.50) prior year; non-GAAP adjusted net loss $7.3M ($0.17/share).
- Cash and equivalents $78.2M at March 31, down from $82.4M at Dec 31; warrant exercise raised net $1.2M in Q1.
- Leadership: Appointed Jim O’Connor CBO & General Counsel; President Geoff Race left, remains as consultant.
- R&D spend rose to $5.3M from $1.4M on trial costs; G&A $11.4M included $6.6M one-time stock comp charge.

## SEC filing metadata
- accession: 0001193125-26-205129
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/0001193125-26-205129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/d947378d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205129
- JSON: https://secwatch.observer/filing/0001193125-26-205129.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205129.txt

## Source-grounded claims
- claim_id: 405943ffcea214b958ef6c7399adff9db580c68c
  claim: Minerva Neurosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $125.4 million, or $2.86 per basic and diluted share, EPS $2.86 per basic and diluted share.
  evidence_excerpt: today reported financial and business updates for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/0001193125-26-205129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.